Financial Statements - Solvay

More documents

Recommendations

Info

156 Solvay Global Annual Report 2008 1 4 7 9 12 2 5 8 10 13 Executive Committee and General Managers 3 6 11 14
Executive Committee 1 | Christian Jourquin Chief Executive Offi cer 2 | Bernard de Laguiche Chief Financial Offi cer 3 | René Degrève Region General Manager NAFTA (member of the Executive Committee until May 13, 2008) 4 | Jacques van Rijckevorsel Group General Manager of the Plastics Sector 5 | Werner Cautreels Group General Manager of the Pharmaceuticals Sector 6 | Vincent De Cuyper Group General Manager of the Chemicals Sector 7 | Jean-Michel Mesland Group General Manager of Research and Technology 8 | Roger Kearns Region General Manager Asia Pacifi c (from July 1, 2008) General Managers Executive Committee and General Managers 2 | Bernard de Laguiche Chief Financial Offi cer 3 | René Degrève Region General Manager NAFTA 4 | Jacques van Rijckevorsel Group General Manager of the Plastics Sector 5 | Werner Cautreels Group General Manager of the Pharmaceuticals Sector 6 | Vincent De Cuyper Group General Manager of the Chemicals Sector 7 | Jean-Michel Mesland Group General Manager of Research and Technology 8 | Roger Kearns Region General Manager Asia Pacifi c (from July 1, 2008) 9 | Jacques Lévy-Morelle Group Corporate Secretary 10 | Marc Duhem Region General Manager Europe 11 | Christian De Sloover Region General Manager Asia Pacifi c (until June 30, 2008) 12 | Daniel Broens Group General Manager Human Resources 13 | Paulo Schirch Region General Manager Mercosur 14 | Dominique Dussard Group General Counsel 157 Solvay Global Annual Report 2008 Executive Committee and General Managers
Page 1 and 2:
Managing Challenges Solvay Global A
Page 3 and 4:
Key fi gures - Solvay Group Financi
Page 5 and 6:
February 1 Caprolactones Solvay con
Page 7 and 8:
Apart from increasing our competiti
Page 9 and 10:
and optional overtime and taking of
Page 11 and 12:
... and Long-Term Value Creation Th
Page 13 and 14:
and using it without limits, the pi
Page 15 and 16:
Chemicals Sales: EUR 3.1 billion -
Page 17 and 18:
2008 : operating result down 19% on
Page 19 and 20:
EUR million 2007 2008 2008/2007 GRO
Page 21 and 22:
Balance sheet Total Equity stood at
Page 23 and 24:
Current profi t before taxes amount
Page 25 and 26:
Robot in Weesp. This 384 wells plat
Page 27 and 28:
Key fi gures [EUR million] 2006 200
Page 29 and 30:
Flagship Products in 2008 Therapeut
Page 31 and 32:
Sales of less important products In
Page 33 and 34:
Sodium bicarbonate. Sodium bicarbon
Page 35 and 36:
Page 37 and 38:
natural resources and limit waste d
Page 39 and 40:
The Organic cluster: Molecular Solu
Page 41 and 42:
Solvay specialty polymers The outst
Page 43 and 44:
Page 45 and 46:
Technological leadership through Re
Page 47 and 48:
production capacities have been inc
Page 49 and 50:
New Business Development OLED. Orga
Page 51 and 52:
future) reacts with atmospheric oxy
Page 53 and 54:
Increasing cultural diversity. Solv
Page 55 and 56:
New career management process In 20
Page 57 and 58:
The 5x5 Matrix The 5x5 Matrix is th
Page 59 and 60:
Investors: responding to growing in
Page 61 and 62:
Financial Statements The following
Page 63 and 64:
Consolidated balance sheet EUR Mill
Page 65 and 66:
Minority interests The increase in
Page 67 and 68:
• IFRIC 15 Agreements for the con
Page 69 and 70:
9. Research and Development costs R
Page 71 and 72:
Key assumptions & key sources of es
Page 73 and 74:
General description of the segments
Page 75 and 76:
Information per primary segment for
Page 77 and 78:
For the Pharmaceuticals Sector, whi
Page 79 and 80:
- Current tax represents the tax pa
Page 81 and 82:
Other information All the Group’s
Page 83 and 84:
The acquisitions in 2008 consist ma
Page 85 and 86:
Alexandria Sodium Carbonate On 17 O
Page 87 and 88:
(20) Capital increase / redemption
Page 89 and 90:
Consolidated balance sheet (22) Int
Page 91 and 92:
(24) Tangible assets (including fi
Page 93 and 94:
(26) Other investments EUR million
Page 95 and 96:
(29) Provisions EUR Million Employe
Page 97 and 98:
The amounts recorded in the balance
Page 99 and 100:
Actuarial assumptions used in deter
Page 101 and 102:
- the risks attached to ongoing lit
Page 103 and 104:
Fair value of fi nancial debts For
Page 105 and 106:
) Balance sheet risk The Group’s
Page 107 and 108:
Financial instruments IAS 39 defi n
Page 109 and 110: (32) Assets held for sale and liabi
Page 111 and 112: Management of Risks Acting responsi
Page 113 and 114: In reference to Raw Materials, in a
Page 115 and 116: Since 2007 a compliance organizatio
Page 117 and 118: Participation in venture capital fu
Page 119 and 120: Compensation report 1. Description
Page 121 and 122: affi liated to the Pension Regulati
Page 123 and 124: Companies leaving the Group Country
Page 125 and 126: SolVin France SA, Paris 75 Pl Vival
Page 127 and 128: Solvay Soda Ash Joint Venture, Hous
Page 129 and 130: FINLAND Pipelife Finland OY, Oulu 5
Page 131 and 132: Summary fi nancial statements of So
Page 133 and 134: STATUTORY AUDITOR’S REPORT To the
Page 135 and 136: Report on the application of the Co
Page 137 and 138: Introduction This report presents t
Page 139 and 140: The Board of Directors noted their
Page 141 and 142: notice of the meeting by mail at th
Page 143 and 144: Year of birth Year of 1st appointme
Page 145 and 146: eing a non-executive director of a
Page 147 and 148: 4.5.2. The Audit Committee At Janua
Page 149 and 150: corresponding to the decision or re
Page 151 and 152: which remained valid for the 2008 f
Page 153 and 154: Manager, a member of the Executive
Page 155 and 156: EUR The Solvay share compared with
Page 157 and 158: ANNEX 1 Audit Committee Mission Sta
Page 159: during the 30 days preceding the st
Page 163 and 164: ABAF: Belgian Financial Analysts As
Page 165 and 166: Shareholders’ Diary - Tuesday May
show all

Financial Statements - Solvay

Create successful ePaper yourself

Delete template?

Save as template?